Literature DB >> 9603132

Surface tension forces in sleep apnea: the role of a soft tissue lubricant: a randomized double-blind, placebo-controlled trial.

R Jokic1, A Klimaszewski, J Mink, M F Fitzpatrick.   

Abstract

Upper airway obstruction in patients with sleep apnea may occur in the absence of a negative intraluminal upper airway pressure. We hypothesized that surface tension forces may play a role in the pathogenesis of obstructive sleep apnea (OSA), and that a topical soft tissue lubricant might reduce the severity of OSA. Ten male patients (age 49 +/- 10 yr [mean +/- SD]; body mass index [BMI] 31 +/- 5 kg/m2) with OSA (apnea-hypopnea index [AHI] 17 +/- 9) were studied. The arousal index was lower with the lubricant treatment than with placebo (mean difference 8; 95% CI 4 to 11 arousals/h; p = 0.001). The AHI was lower, in each of the 10 patients, on the lubricant treatment than the placebo (mean change 10, 95% CI 6 to 13; p = 0.0003). The lower AHI with lubricant as compared with placebo was present in both supine (mean difference 13; 95% CI 5 to 20; p = 0.006) and nonsupine (mean difference 6; 95% CI 0 to 12; p = 0.05) positions. There was no significant difference in sleep architecture between the lubricant and placebo treatments. Application of a topical lubricant consistently reduced the severity of OSA. This implies a pathogenetic role for surface tension forces in OSA, and a potential role for surface tension-reducing agents in the treatment of OSA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9603132     DOI: 10.1164/ajrccm.157.5.9708070

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  18 in total

Review 1.  Pathophysiology of adult obstructive sleep apnea.

Authors:  Danny J Eckert; Atul Malhotra
Journal:  Proc Am Thorac Soc       Date:  2008-02-15

2.  Saliva production and surface tension: influences on patency of the passive upper airway.

Authors:  J C M Lam; K Kairaitis; M Verma; J R Wheatley; T C Amis
Journal:  J Physiol       Date:  2008-09-25       Impact factor: 5.182

3.  Upper airway surface tension but not upper airway collapsibility is elevated in primary Sjögren's syndrome.

Authors:  Cassie J Hilditch; R Doug McEvoy; Kate E George; Courtney C Thompson; Melissa K Ryan; Maureen Rischmueller; Peter G Catcheside
Journal:  Sleep       Date:  2008-03       Impact factor: 5.849

Review 4.  Impact of concomitant medications on obstructive sleep apnoea.

Authors:  Ingrid Jullian-Desayes; Bruno Revol; Elisa Chareyre; Philippe Camus; Céline Villier; Jean-Christian Borel; Jean-Louis Pepin; Marie Joyeux-Faure
Journal:  Br J Clin Pharmacol       Date:  2016-11-24       Impact factor: 4.335

Review 5.  Sleep x 9: an approach to treatment of obstructive sleep apnoea/hypopnoea syndrome including upper airway surgery.

Authors:  C F Ryan
Journal:  Thorax       Date:  2005-07       Impact factor: 9.139

Review 6.  Understanding Pathophysiological Concepts Leading to Obstructive Apnea.

Authors:  Eric Deflandre; Alexander Gerdom; Christine Lamarque; Bernard Bertrand
Journal:  Obes Surg       Date:  2018-08       Impact factor: 4.129

Review 7.  The importance of obstructive sleep apnoea and hypopnea pathophysiology for customized therapy.

Authors:  Marcello Bosi; Andrea De Vito; Riccardo Gobbi; Venerino Poletti; Claudio Vicini
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-07-28       Impact factor: 2.503

8.  Influence of breathing route on upper airway lining liquid surface tension in humans.

Authors:  Manisha Verma; Margaret Seto-Poon; John R Wheatley; Terence C Amis; Jason P Kirkness
Journal:  J Physiol       Date:  2006-05-11       Impact factor: 5.182

Review 9.  Pathophysiology of sleep apnea.

Authors:  Jerome A Dempsey; Sigrid C Veasey; Barbara J Morgan; Christopher P O'Donnell
Journal:  Physiol Rev       Date:  2010-01       Impact factor: 37.312

Review 10.  Potential therapeutic targets in obstructive sleep apnoea.

Authors:  Julian P Saboisky; Nancy L Chamberlin; Atul Malhotra
Journal:  Expert Opin Ther Targets       Date:  2009-07       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.